1. Introduction {#sec1}
===============

Hashimoto\'s thyroiditis or chronic autoimmune thyroiditis is the most common cause of acquired hypothyroidism or goiter in children over 6 years of age in iodine-sufficient areas of the world. The patients generally are genetically predisposed to the disease and family history of thyroid disorder is seen in up to 30--40% of patients \[[@B1], [@B2]\]. This condition is characterized by lymphocytic infiltration and destruction of thyroid parenchyma and high serum concentration of autoantibodies against thyroid tissue. Documenting high serum concentrations of anti-thyroid peroxidase (anti-TPO) and/or anti-thyroglobulin (anti-TG) autoantibodies is sufficient to diagnose chronic autoimmune thyroiditis as the cause of a patient\'s hypothyroidism \[[@B3]\]. The prevalence of autoimmune thyroiditis (defined by characteristic echographic pattern and elevated concentration of anti-TPO and/or anti-TG autoantibodies) in schoolchildren is approximately 2.5% \[[@B4]\].

The cause of thyroid autoimmunity is a combination of genetic and environmental factors. The genetic factors which are associated with Hashimoto\'s thyroiditis lie in the human leukocyte antigen (HLA) complex, while an association with cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or a closely linked gene has also been described \[[@B5], [@B6]\].

Type 1 diabetes mellitus, like autoimmune thyroiditis, is an organ-specific autoimmune disease which is caused by a complex interaction of genetic and environmental factors. It is reported that HLA and CTLA-4 polymorphism is associated with type 1 diabetes mellitus as well as with autoimmune thyroid disease \[[@B4], [@B5], [@B7]\].

Most patients with newly diagnosed type 1 diabetes mellitus have elevated concentrations of autoantibodies against Langerhans islet *β*-cells. The antigens for these antibodies are insulin (IAA), glutamic acid decarboxylase (GAD), insulinoma associated autoantigen 2 (IA2A), and zinc transporter 8 (ZnT8A). The autoantibodies appear in the blood at as early as 6 months of age and are detectable several years before the clinical manifestation of the disease \[[@B8], [@B9]\]. These antibodies can have both a diagnostic and predictive value for type 1 diabetes mellitus.

The incidence of type 1 diabetes has been increasing worldwide for several decades \[[@B10]\]. If the incidence rate continues to increase on the existing path, there is the risk of doubling of global incidence \[[@B7]\].

There is large evidence that autoimmunity against the thyroid gland in patients with type 1 diabetes mellitus is increased by up to 20--30% \[[@B11], [@B12]\]. In contrast, little is known about anti-islet cell autoimmune status in patients with autoimmune thyroid disease. Therefore we evaluated the concentration of antibodies against glutamic acid decarboxylase (GAD) which are widely used as a diagnostic and predictive tool for type 1 diabetes mellitus.

2. Design and Methods {#sec2}
=====================

2.1. Subjects {#sec2.1}
-------------

We studied Georgian school-aged children, up to 16 years of age, who had been diagnosed as having chronic autoimmune thyroiditis. The patients were recruited from the V. Iverieli Endocrinology Metabology Dietology Center "ENMEDIC," a clinic which has nearly a hundred years of experience in the field of endocrinology and to which patients with endocrine pathology are referred from all regions of Georgia. The exclusion criteria for this study were diabetes mellitus, first-degree relatives with type 1 diabetes mellitus, other autoimmune conditions, Turner Syndrome, and Down Syndrome. The diagnosis of chronic autoimmune thyroiditis was established by the responsible pediatric endocrinologist, confirmed by elevated levels of serum thyrotropin (TSH) and autoantibodies against thyroid peroxidase and/or thyroglobulin. The control group was chosen from randomly selected schools in different regions of Georgia. The exclusion criteria for control subjects were first-degree relatives with type 1 diabetes mellitus and a history of thyroid disease. The serum concentrations of anti-TPO and anti-TG antibodies were investigated in the control group and were not elevated, within reference range, in all subjects recruited in this group. Positivity of GAD antibodies was compared in two groups.

2.2. Assays {#sec2.2}
-----------

Glutamic acid decarboxylase antibodies were detected using quantitative ELISA (produced by RSR Limited, UK). The assay has specificity of 99% and sensitivity of 72%. Cut-off value for positive results was established as ≥5 U/mL. To assess the plasma concentration of anti-TPO and anti-TG antibodies we used the ADVIA Centaur XP anti-TPO and anti-TG assays (produced by Siemens) using chemiluminescent technology. Samples were defined as anti-TPO positive when the level was higher than 60 IU/mL and anti-TG positive when the level was higher than 60 IU/mL. We use ADVIA Centaur XP TSH assay (produced by Siemens) for measurement of TSH plasma concentration, and reference range was 04--4.0 *μ*IU/mL, and we use ADVIA Centaur XP FT4 assay (produced by Siemens) for measurement of free thyroxine (FT4) plasma concentration, and reference range was 0.8--2.0 ng/dL.

2.3. Statistical Analyses {#sec2.3}
-------------------------

Fisher\'s exact probability test was used to assess the significance of differences of GAD positivity between the patients with autoimmune thyroiditis and healthy control subjects. Statistical significance was defined as *P* \< 0.05.

2.4. Ethical Aspects {#sec2.4}
--------------------

The study was approved by the Local Ethical Committee of V. Iverieli Endocrinology Metabology Dietology Center "ENMEDIC," study number ENM-001, in agreement with Helsinki Declaration (1977) regarding ethical standards for clinical studies in medicine. Informed consent was obtained from the children and/or from their legal guardians.

3. Results {#sec3}
==========

The patient group consisted of 41 children (10 males and 31 females), aged from 6 to 16 (mean 13.15; median 13.00; SD 2.231). As the control group there were 51 healthy subjects (17 males and 34 females), age from 6 to 16 years (mean 12.96; median 13.00; SD 2.441).

In the study group 37 of the 41 patients (90.2%) were receiving treatment with levothyroxine, three (7.3%) had primary hypothyroidism (without goiter) with TSH elevation (TSH values were from 11.57 to 137.42 *μ*IU/mL; median: 74.89), six (14.6%) had subclinical hypothyroidism (without goiter) (TSH values were from 5.12 to 7.36 *μ*IU/mL; median: 5.28), five (12.2%) had primary hypothyroidism with diffuse goiter (TSH values were from 15.24 to 150.01 *μ*IU/mL; median: 37.45), 21 (51.2%) had subclinical hypothyroidism with diffuse goiter (TSH values were from 4.43 to 6.28 *μ*IU/mL; median: 4.98), four (9.8%) had subclinical hypothyroidism with nodular goiter (TSH values were from 4.67 to 4.99 *μ*IU/mL; median: 4.88), one had primary hypothyroidism with nodular goiter, and one presented with hyperthyroidism and diffuse goiter ([Table 1](#tab1){ref-type="table"}).

Of the 41 patients with autoimmune thyroiditis 4 (9.8%) were positive for GAD antibodies and their details are shown in [Table 2](#tab2){ref-type="table"}. None of the 51 control subjects was positive for GAD.

In the four GAD positive patients three had diffuse goiter and one had nodular goiter, and among them two had primary hypothyroidism and two had subclinical hypothyroidism ([Table 2](#tab2){ref-type="table"}).

The frequency of GAD positivity in the autoimmune thyroiditis group was significantly higher than in the control subjects (*P* = 0.036) ([Table 3](#tab3){ref-type="table"}).

So far the GAD positive patients are under the close observation. We plan to reevaluate the patients annually. The assessment of other anti-islet antibodies, antibodies against adrenal glands, and IgA tissue transglutaminase antibodies is also planned.

4. Discussion {#sec4}
=============

Glutamic acid decarboxylase of 65 kDa (GAD65) is one of the major autoantigens for type 1 diabetes mellitus. Glutamic acid decarboxylase catalyzes the synthesis of gamma-aminobutyric acid (GABA), which is known as a major inhibitory neurotransmitter in the central nervous system (CNS), but it is also present outside the CNS. It is also found in *β*-cells of islets of Langerhans, but its functional role remains largely unknown. Antibodies to glutamic acid decarboxylase serve as a predictor and marker of type 1 diabetes mellitus \[[@B13]\]. The predictive sensibility of GAD antibodies for type 1 diabetes mellitus in the general population is approximately 50% \[[@B14]\]. In our study we show that the frequency of GAD positivity in the autoimmune thyroiditis group was significantly higher than in the control subjects (*P* = 0.036). Our findings support the concept that patients with autoimmune thyroid disease may be at high risk of developing type 1 diabetes mellitus, as is concluded by the studies of healthy children from the general population, which show marked increase of incidence of type 1 diabetes mellitus in subjects with positive serum antibodies against pancreatic islet cells \[[@B15], [@B16]\].

According to our findings we concluded that the screening for GAD antibodies in patients with autoimmune thyroid disease may reveal the individuals with increased risk of developing type 1 diabetes mellitus; however, the importance of screening autoantibodies and then follow-up of antibody positive patients remains controversial, as the disease cannot be prevented so far \[[@B17]\]. But it is still very important to reveal the different risk groups as recent studies revealed a markedly reduced rate of diabetic ketoacidosis and other complications at onset of type 1 diabetes in individuals screened for islet autoantibodies \[[@B18]\].

5. Conclusion {#sec5}
=============

In the study we found that the frequency of GAD antibody positivity in autoimmune thyroiditis patients was significantly higher (9.8%, *P* = 0.036) than in the control group. Our findings support the concept that patients with autoimmune thyroid disease may develop type 1 diabetes mellitus in future life.

Though the onset of type 1 diabetes cannot be prevented, it is still very important to reveal the different risk groups as the knowledge of the increased risk can help to prevent acute onset of the disease with ketoacidosis and concomitant morbidities.
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###### 

Clinical characteristics of 41 patients aged 6 to 16 with autoimmune thyroiditis and the control group.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                   Total\   Females/males   TSH *µ*IU/mL\           Anti-TPO IU/mL median (range)   Anti-TG IU/mL\
                                                   *N*                      median (range)                                          median (range)
  ------------------------------------------------ -------- --------------- ----------------------- ------------------------------- --------------------------
  Primary hypothyroidism (without goiter)          3        3/0             74.89 (11.57--137.42)   156.9 (153.13--318.05)          342.69 (217.01--375.21)

  Subclinical hypothyroidism (without goiter)      6        4/2             5.28 (5.12--7.36)       239.59 (78.07--569.56)          379.84 (82.7--482.35)

  Primary hypothyroidism with diffuse goiter       5        4/1             37.45 (15.24--150.01)   480.27 (206--653.38)            ---

  Subclinical hypothyroidism with diffuse goiter   21       15/6            4.98 (4.43--6.28)       211.57 (72.95--517.32)          292.19 (136.47--546.24)

  Primary hypothyroidism with nodular goiter       1        1/0             94.78                   517.32                          ---

  Subclinical hypothyroidism with nodular goiter   4        3/1             4.88 (4.67--4.99)       243.98 (145.22--526.75)         619.53 (214.15--1024.91)

  Diffuse goiter with hyperthyroidism              1        1/0             0.01                    238.78                          ---

  Levothyroxine treatment^*∗*^                     37       27/10           5.46 (4.43--150.01)     216.35 (72.95--653.38)          333.42 (82.7--1024.91)

  All patients                                     41       31/10           5.26 (0.01--150.01)     236.35 (72.95--653.38)          333.42 (82.7--1024.91)

  Control group                                    51       34/17           1.84 (0.53--3.78)       36.91 (25.02--51.35)            39.85 (29.76--52.06)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Including all patients from all subgroups which receive levothyroxine treatment.

###### 

Clinical characteristics of GAD positive patients.

                                     Patient 1        Patient 2        Patient 3        Patient 4
  ---------------------------------- ---------------- ---------------- ---------------- ----------------
  Sex                                Female           Female           Female           Male
  Age                                11               14               12               13
  FT4 titre pmol/L (first visit)                      12.61            11.33            13.64
  TSH titre *µ*IU/mL (first visit)   94.78            5.12             15.24            4.43
  Anti-TPO titre IU/mL               517.32           327.25           480.27           95
  Anti-TG titre IU/mL                                 433.96                             
  Anti-GAD titre U/mL                231.01           413.79           5.92             23.56
  Type of goiter                     Nodular goiter   Diffuse goiter   Diffuse goiter   Diffuse goiter
  Current dose of LT4 *µ*g/day       100              125              112.5            100

###### 

Frequency of GAD antibodies in patients with autoimmune thyroiditis and the control subjects.

                              Patients with autoimmune thyroiditis   Control subjects     *P*
  --------------------------- -------------------------------------- ------------------ -------
    *n*                       41                                     51                  
  Age (years)                 13.39 ± 1.96                           12.98 ± 2.39        
  Sex (male/female)           10/31                                  17/34               
  Anti-GAD positive (*n*/%)   4/9.8                                  0                  0.036
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